The Phase 2/3 miss raises doubts about mRNA cancer vaccine approaches and weighed on BioNTech shares.

Early data could make Verastem competitive in the crowded KRAS inhibitor field, where a rival drug struggled.

The approval adds another entrant to the fast-growing obesity treatment market.

Executives said there is a lot of exploring to do after initial melanoma vaccine success, and Moderna shares rallied on the news.

A subcutaneously administered RNA interference medicine reduced levels of a protein implicated in the disease.

A revamped regulatory approach may reduce guesswork for investors weighing rare disease drug approvals.

The former chiefs said the staff exodus robbed the FDA of institutional knowledge that will take years to restore.

The largely unregulated peptide injections are favored by HHS secretary Robert F. Kennedy Jr.

The listing adds to a wave of young biotechs using AI to accelerate research.

Authorities have struggled to contain the outbreak in Congo amid thousands of confirmed cases.

The company monetized vouchers won from recent gene therapy approvals to fund pipeline expansion.

Scientists hope to replicate the cryopreservation findings with human organs.

The in vivo CAR-T approach aims to generate immune cells inside the body rather than through ex vivo engineering.

Prosecutors said the company filled unnecessary prescriptions that fueled the opioid epidemic.

The acceptance advances a biosimilar challenge to Merck's blockbuster immunotherapy.

The expansion follows a period of regulatory whiplash for the company.

Nearly 40% of FDA advisory meetings over a 20-year period included patient or consumer reps with active industry ties.

The Belgian startup, chaired by former Galapagos CEO Paul Stoffels, assumes control of divested cell therapies.